ICRF and Lung Cancer Research Foundation Ongoing Partnership to Treat KRAS-Mutant Cancers

November is Lung Cancer Awareness Month, and ICRF and the Lung Cancer Research Foundation (LCRF) are proud to be partners on a three-year research project led by Professor Joel Yisraeli at Hebrew University of Jerusalem. Building on previous ICRF-funded research, the project explores a new approach to treating KRAS-mutant cancers by targeting IGF2BP1, a protein involved in cancer development.

We spoke with Prof. Yisraeli about the research, the team’s promising early findings, and the next steps toward evaluating this potential treatment approach.

“We are very excited about the ongoing collaboration between Israel Cancer Research Fund and the Lung Cancer Research Foundation to advance new approaches to treating lung cancer, including KRAS-mutant cancers. Our small-molecule inhibitor AVJ16, which targets IGF2BP1, has shown promising results. We are now developing bivalent molecules that target and degrade this protein. These molecules are showing encouraging effects in lung adenocarcinoma cells, and we look forward to testing them in preclinical models.”

Read the press release announcement.

Learn more about Prof. Joel Yisraeli.